Docetaxel defeats doxorubicin in adjuvant therapy arena

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1526, 2006-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide

By Liubao Peng

PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. : 873-886

Adis International

Access to resources Recommend Favorite

Neoadjuvant docetaxel, vinorelbine and trastuzumab prior to surgery and adjuvant therapy is active in patients with HER-2 breast cancer

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Cyclophosphamide/docetaxel/doxorubicin: Extramedullary haematopoiesis: case report

Reactions Weekly, Vol. 1, Iss. 1253, 2009-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Docetaxel delivers over doxorubicin for early breast cancer

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Doxorubicin + docetaxel vs standard chemo in breast cancer

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite